Hexafluoro

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561683

CAS#: 128481-73-2

Description: Hexafluoro, also known as B 1673141, is an inhibitor of the phosphorylation of DRP1. It stimulates a phenotype suggestive of respiration through mitochondrial normalization and demonstrates activity in Vemurafenib-resistant melanoma in vivo.


Chemical Structure

img
Hexafluoro
CAS# 128481-73-2

Theoretical Analysis

MedKoo Cat#: 561683
Name: Hexafluoro
CAS#: 128481-73-2
Chemical Formula: C21H18F6O2
Exact Mass: 416.12
Molecular Weight: 416.360
Elemental Analysis: C, 60.58; H, 4.36; F, 27.38; O, 7.69

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Hexafluoro; B 1673141; B-1673141; B1673141;

IUPAC/Chemical Name: Bistrifluoromethyl-bis-(4-hydroxy-3-allylphenyl) methane

InChi Key: QGHDLJAZIIFENW-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H18F6O2/c1-3-5-13-11-15(7-9-17(13)28)19(20(22,23)24,21(25,26)27)16-8-10-18(29)14(12-16)6-4-2/h3-4,7-12,28-29H,1-2,5-6H2

SMILES Code: C=CCC1=CC(C(C(F)(F)F)(C(F)(F)F)C2=CC=C(O)C(CC=C)=C2)=CC=C1O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 416.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Lin H, Song P, Zhao Y, Xue LJ, Liu Y, Chu CQ. Targeting Th17 Cells with Small Molecules and Small Interference RNA. Mediators Inflamm. 2015;2015:290657. doi: 10.1155/2015/290657. Epub 2015 Dec 17. Review. PubMed PMID: 26792955; PubMed Central PMCID: PMC4697089.

2: Pazos G, Rivadulla ML, Pérez-García X, Gandara Z, Pérez M. Gemini analogs of vitamin D. Curr Top Med Chem. 2014;14(21):2388-97. Review. PubMed PMID: 25486935.

3: Mazzaferro S, Pasquali M, Conte C, Mandanici G, Muci M, Lavini R. Vitamin D receptor activators. Int J Artif Organs. 2009 Feb;32(2):101-7. Review. PubMed PMID: 19363782.

4: Morii H. [Falecalcitriol as a new therapeutic agent for secondary hyperparathyroidism]. Clin Calcium. 2005 Jan;15(1):29-33. Review. Japanese. PubMed PMID: 15632470.

5: Miwa N, Akiba T. [The trend in the development of the active vitamin D3 and its analogues]. Nihon Rinsho. 2004 May;62 Suppl 5:364-7. Review. Japanese. PubMed PMID: 15197946.

6: Ohtsuka N, Urayama K. [Pharmacological action and clinical effects of falecalcitriol, a highly potent derivative of active vitamin D3]. Nihon Yakurigaku Zasshi. 2002 Dec;120(6):427-36. Review. Japanese. PubMed PMID: 12528474.

7: Adorini L, Penna G, Giarratana N, Uskokovic M. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J Cell Biochem. 2003 Feb 1;88(2):227-33. Review. PubMed PMID: 12520519.

8: Uskokovic MR, Norman AW, Manchand PS, Studzinski GP, Campbell MJ, Koeffler HP, Takeuchi A, Siu-Caldera ML, Rao DS, Reddy GS. Highly active analogs of 1alpha,25-dihydroxyvitamin D(3) that resist metabolism through C-24 oxidation and C-3 epimerization pathways. Steroids. 2001 Mar-May;66(3-5):463-71. Review. PubMed PMID: 11179755.

9: Tohma H. [Development of novel oxidation reactions using hypervalent iodine reagents and their application to total synthesis of biologically active natural products]. Yakugaku Zasshi. 2000 Jul;120(7):620-9. Review. Japanese. PubMed PMID: 10920716.